ArticleJournal of vascular surgery2016
Metformin treatment status and abdominal aortic aneurysm disease progression.
Article in Journal of vascular surgery, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 70 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
70 citing papers in PubMed, 5 syntheses or guidelines pooled it, 160 citations in OpenAlex.
- The association between diabetes and abdominal aortic aneurysms in men: results of two Danish screening studies, a systematic review, and a meta-analysis of population-based screening studies.BMC cardiovascular disorders · 2023Pooled it
- The role of dipeptidyl peptidase-IV in abdominal aortic aneurysm pathogenesis: A systematic review.Vascular medicine (London, England) · 2022Pooled it
- Association Between Metformin and Abdominal Aortic Aneurysm: A Meta-Analysis.Frontiers in cardiovascular medicine · 2022Pooled it
- The Protective Effect of Metformin on Abdominal Aortic Aneurysm: A Systematic Review and Meta-Analysis.Frontiers in endocrinology · 2021 · on this mapPooled it
- Pharmacotherapy in Clinical Trials for Abdominal Aortic Aneurysms: A Systematic Review and Meta-Analysis.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/HemostasisPooled it
- MetAAA Trial Patients Receiving Metformin Therapy Show Limited Improvement in Quality of Life Compared to AAA Patients with Placebo Intake-A Double-Blind, Randomized, and Placebo-Controlled Trial.Medical sciences (Basel, Switzerland) · 2025Trial
- Metformin Use and Long-term Outcomes Including Aneurysm Sac Dynamics Following EVAR for Infrarenal Abdominal Aortic Aneurysm: "A Retrospective Study".Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists · 2026Article
- Glucagon-like peptide-1 receptor agonists are associated with reduced abdominal aortic aneurysm-related events.Journal of vascular surgery · 2026Article
- Mitochondrial Functional Capacity Is Impaired in Angiotensin II-Infused Mice and Not Recovered by Metformin.Biomedicines · 2026Article
- Metformin does not attenuate angiotensin II-induced aortic aneurysms in low-density lipoprotein receptor deficient mice.Scientific reports · 2025Article
- CCDC80 Protects against Aortic Dissection and Rupture by Maintaining the Contractile Smooth Muscle Cell Phenotype.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Review
- Metformin and Risks of Aortic Aneurysm and Aortic Dissection: A Mendelian Randomization Study.Reviews in cardiovascular medicine · 2025Article
- Hyperglycemia inhibits AAA expansion: examining the role of lysyl oxidase.American journal of physiology. Heart and circulatory physiology · 2025Article
- The Impact of Diabetes Mellitus and Metformin Use on Outcomes After Endovascular Aneurysm Repair.Journal of clinical medicine · 2025Article
- The first abdominal aortic aneurysm organoid model replicates complex microenvironment forTheranostics · 2025Article
- Risk factors for thoracic aortic aneurysm and dissection among diabetic patients: a nationwide population-based study.Frontiers in cardiovascular medicine · 2025Article
- Association between diabetes status and long-term outcomes following open and endovascular repair of infrarenal abdominal aortic aneurysms.Journal of vascular surgery · 2024Article
- Metformin Therapeutic Targets for Aortic Aneurysms: A Mendelian Randomization and Colocalization Study.Reviews in cardiovascular medicine · 2024Article
- Influence of cardiometabolic medications on abdominal aortic aneurysm growth in the UK Aneurysm Growth Study: metformin and angiotensin-converting enzyme inhibitors associated with slower aneurysm growth.The British journal of surgery · 2024Article
10 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
Abstract
objectiveIn population-based studies performed on multiple continents during the past two decades, diabetes mellitus has been negatively associated with the prevalence and progression of abdominal aortic aneurysm (AAA) disease. We investigated the possibility that metformin, the primary oral hypoglycemic agent in use worldwide, may influence the progression of AAA disease.
methodsPreoperative AAA patients with diabetes were identified from an institutional database. After tabulation of individual cardiovascular and demographic risk factors and prescription drug regimens, odds ratios for categorical influences on annual AAA enlargement were calculated through nominal logistical regression. Experimental AAA modeling experiments were subsequently performed in normoglycemic mice to validate the database-derived observations as well as to suggest potential mechanisms of metformin-mediated aneurysm suppression.
resultsFifty-eight patients met criteria for study inclusion. Of 11 distinct classes of medication considered, only metformin use was negatively associated with AAA enlargement. This association remained significant after controlling for gender, age, cigarette smoking status, and obesity. The median enlargement rate in AAA patients not taking oral diabetic medication was 1.5 mm/y; by nominal logistic regression, metformin, hyperlipidemia, and age ≥70 years were associated with below-median enlargement, whereas sulfonylurea therapy, initial aortic diameter ≥40 mm, and statin use were associated with above-median enlargement. In experimental modeling, metformin dramatically suppressed the formation and progression, with medial elastin and smooth muscle preservation and reduced aortic mural macrophage, CD8 T cell, and neovessel density.
conclusionsEpidemiologic evidence of AAA suppression in diabetes may be attributable to concurrent therapy with the oral hypoglycemic agent metformin.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.